Three complementary protein expression platforms for challenging targets: scalable membrane protein production in ultra-high-density photobioreactors, rapid direct mRNA delivery to plant protoplasts, and transient agroinfiltration with self-replicating viral vectors. Supports rapid screening and scale-up across diverse protein classes, with functional recovery demonstrated for membrane proteins and pilot-scale bioreactor validation.
CALYX Bioprocess Technologies offers a portfolio of complementary recombinant protein expression platforms designed to address difficult-to-express proteins, particularly membrane proteins and targets where conventional transcriptional regulation limits yield. The three routes span rapid small-scale screening through scalable production:
This multi-platform approach lets partners select the expression strategy best suited to their protein class, yield requirements, and development timeline.
Membrane protein platform
Direct mRNA delivery platform
Transient agroinfiltration platform
The membrane protein platform has reached pilot scale, with patented bioreactor technology, orders-of-magnitude yield improvement, and functional protein recovery demonstrated. The direct mRNA delivery system is in active optimization for rapid small-scale screening. The agroinfiltration and viral-vector platform has been refined over many years; near-term steps include updating regulatory permits for viral vectors and establishing comparative expression data across plant tissues. Future validation plans include selecting 3–5 protein targets with existing functional assays, establishing microgram-level purification from simple culture, and evaluating scale-up for the most promising candidates. The platform portfolio is available for collaborative development, sponsored research, licensing, and pilot trial engagement.